Ujvira 100mg Injection
₹20,500.00Current price is: ₹20,500.00. Original price was: ₹34,728.75.
Brand Name: Ujvira
Category: Anti Cancer
Manufacturer: Zydus Life sciences
Composition: Trastuzumab emtansine
1 Vial
Ujvira 100mg Injection is a monoclonal antibody with Trastuzumab emtansine as its active ingredient and is mainly used for treating HER2-positive cancers, such as breast cancers.
Tell your healthcare provider all of the medications you use, as interactions can occur. You should not take this medicine if you are pregnant or breast-feeding. Use an effective form of birth control to prevent pregnancy during your treatment.
This product is non-returnable.
Product Description
Ujvira 100mg Injection is a monoclonal antibody with Trastuzumab emtansine as its active ingredient and is mainly used for treating HER2-positive cancers, such as breast cancers.
Uses of Ujvira 100mg Injection:
- Breast Cancer
How does Ujvira 100mg Injection work?
It targets the HER2 receptor, a protein which is overexpressed on the surface of some cancer cells. Trastuzumab connects to HER2 and inhibits the signaling pathways that stimulate cell growth and survival, slowing down tumor growth and labeling the cells for destruction by the immune system.
How to Use & Dosage
The dose is based on body weight and is usually given intravenously every three weeks. Treatment plan and dose may be influenced by clinical guidelines and individual needs.
The drug is given by injection into a vein. It is given by a trained health professional in a hospital or clinic.
Ask your pediatrician about the use of this medication in children. It is not indicated for use in children.
Possible Side Effects:
- Nausea
- Vomiting
- Loss of appetite
- Diarrhea
- Fatigue
- Dizziness
- Sweating
- Stomatitis (mouth sores)
- Hand-foot syndrome
- Cardiotoxicity
- Liver enzyme elevation
Safety Advise:
🫘 Kidney
Periodic tests of kidney function are recommended because the drug can be toxic, especially in patients with pre-existing disease. Talk to your health care provider.
🫀 Liver
The drug can be toxic, particularly in patients with pre-existing conditions, so periodic tests of liver function are recommended. Please discuss with your healthcare professional.
🤰 Pregnancy
Ujvira is contraindicated in pregnancy as it may cause harm to the fetus. Talk to your health care provider about this.
🤱 Breastfeeding
Breastfeeding: The drug passes into breast milk. Do not breastfeed. Talk to your doctor.
Storage Instructions:
Store at below 25°C. Protect from light and do not freeze.
References
- Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.
- Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill.
- Lambert JM, Chari RVJ. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. Journal of Medicinal Chemistry. 2014;57(16):6949-6964.
- Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine. 2012;367(19):1783-1791.
- Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) Prescribing Information. Full Prescribing Information, U.S. Food and Drug Administration.
Disclaimer:
IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.